Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Henry G. Grabowski"'
Publikováno v:
Journal of medical economics. 24(1)
To provide updated evidence in a series of analyses of U.S. trends over the past two decades in key financial metrics for branded drugs: market exclusivity periods (MEPs, the time between launch and first generic entry) for new molecular entities (NM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1674b434f11aa7215d82f13a317cb0b3
https://pubmed.ncbi.nlm.nih.gov/34253119
https://pubmed.ncbi.nlm.nih.gov/34253119
Publikováno v:
American Journal of Health Economics. 3:33-59
The pharmaceutical industry has experienced a large number of patent challenges in recent years. Key catalysts for this were legal and regulatory changes that awarded 180-day exclusivity rights for first-filing generic firms not only on the basis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6e423923200dfe476eb5a7074ddda48
https://doi.org/10.1162/ajhe_a_00066
https://doi.org/10.1162/ajhe_a_00066
Autor:
P. Ann Hedlund Hoppe, Raffi Tachdjian, Henry G. Grabowski, Mark W. Skinner, Stuart J. Youngner, James F. Crone, Richard Manning
Publikováno v:
Transfusion. 56:2889-2894
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc896bc4966c5ea56f6bce77d0696ab
https://doi.org/10.1111/trf.13764
https://doi.org/10.1111/trf.13764
Autor:
Richard Manning, Henry G. Grabowski
Publikováno v:
International Journal of the Economics of Business. 23:149-166
Human blood plasma and its derivative therapies have been used therapeutically for more than 50 years, after first being widely used to treat injuries during World War II. In certain countries, manufacturers of these therapies – known as plasma-der
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73a2991925e4232dcc67f48abd1ab0e5
https://doi.org/10.1080/13571516.2016.1182690
https://doi.org/10.1080/13571516.2016.1182690
Publikováno v:
Health Affairs. 34:302-310
Patents and other forms of intellectual property protection play essential roles in encouraging innovation in biopharmaceuticals. As part of the "21st Century Cures" initiative, Congress is reviewing the policy mechanisms designed to accelerate the d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15e9e45a2b3bd799a916fb13ffad835d
https://doi.org/10.1377/hlthaff.2014.1047
https://doi.org/10.1377/hlthaff.2014.1047
Publikováno v:
SSRN Electronic Journal.
In September 2015, the first biosimilar drug, Zarxio, was launched on the U.S. market. While the impact of generic entry on the small molecule branded market in the U.S. is well-understood, the impact of biosimilar entry on the large molecule biologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c659b5ab1ccbcbbd8c8077665dad13e
https://doi.org/10.2139/ssrn.3016138
https://doi.org/10.2139/ssrn.3016138
Publikováno v:
Health Affairs. 33:1048-1057
In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars-drugs that are very similar but not identical to a reference biological product and cost less. Because bringing biosimilars to the market
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24cfbdbf968ca319e6f5eb15305674f0
https://doi.org/10.1377/hlthaff.2013.0862
https://doi.org/10.1377/hlthaff.2013.0862
Publikováno v:
Journal of Medical Economics. 17:207-214
To provide evidence on recent trends in: (1) market exclusivity periods (MEPs, the time between launch of a brand-name drug and its first generic competitor) for new molecular entities (NMEs); (2) the likelihood and timing of patent challenges under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34571ac0c643933079658dbf919e39fa
https://doi.org/10.3111/13696998.2013.873723
https://doi.org/10.3111/13696998.2013.873723
Publikováno v:
Journal of medical economics. 19(9)
To provide updated evidence on US trends in: market exclusivity periods (MEPs, time between brand-name drug launch and first generic competitors) for new molecular entities (NMEs); likelihood, timing and number of Hatch-Waxman Act Paragraph IV patent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e8bbe3e8a824c6257dc867dbe31e8bb
https://pubmed.ncbi.nlm.nih.gov/27064194
https://pubmed.ncbi.nlm.nih.gov/27064194
Publikováno v:
Health Affairs
Health Affairs, Project HOPE, 2011, 30 (11), pp.2157-2166. ⟨10.1377/hlthaff.2010.0270⟩
Health Affairs, Project HOPE, 2011, 30 (11), pp.2157-2166. ⟨10.1377/hlthaff.2010.0270⟩
International audience; The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7fa02ef94093cb1bf1b131e11c00fc2
https://doi.org/10.1377/hlthaff.2010.0270
https://doi.org/10.1377/hlthaff.2010.0270